Immunomet Therapeutics Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jan 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 13, 2027The maintenance fee for Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient (US 10,376,480) comes due Feb 13, 2027. Unpaid by Aug 13, 2027, it lapses early.
- 1 fee due Mar 15, 2027The maintenance fee for Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient (US 9,133,110) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
- 1 fee due May 28, 2027The maintenance fee for Pharmaceutical Compositions for Preventing or Treating Inflammatory Disease, Autoimmune Disease, or Combination Thereof, and Method for Using Same (US 11,826,324) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
- 1 fee due Sep 17, 2027The maintenance fee for Guanidine compounds and use thereof (US 10,590,081) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.
- 2 fees due Oct 21 to 26, 2027 · next Oct 21
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,416,098 | Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient In force · From the USPTO record | In force | From the USPTO record | |
| US 9,464,042 | Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient In force · From the USPTO record | In force | From the USPTO record | |
| US 9,993,446 | Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient In force · From the USPTO record | In force | From the USPTO record | |
| US 10,376,480 | Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient In force · From the USPTO record | In force | From the USPTO record | |
| US 9,133,110 | Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient In force · From the USPTO record | In force | From the USPTO record | |
| US 9,321,742 | N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same In force · From the USPTO record | In force | From the USPTO record | |
| US 9,540,325 | N1-cyclic amine-N5-substituted phenyl biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same In force · From the USPTO record | In force | From the USPTO record | |
| US 9,884,821 | N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same In force · From the USPTO record | In force | From the USPTO record | |
| US 10,252,996 | N1-CYCLIC AMINE-N5-SUBSTITUTED Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same In force · Low confidence | In force | Low confidence | |
| US 10,058,558 | Pharmaceutical composition comprising N1-cyclic amine-N5-substituted biguanide derivatives as an ingredient for preventing or treating fibrosis In force · From the USPTO record | In force | From the USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 1 abandoned · 3 no status recorded